NCT05041153 2026-01-12Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal AdenocarcinomaM.D. Anderson Cancer CenterPhase EARLY_PHASE1 Recruiting15 enrolled